Biote (NASDAQ: BTMD), a leading provider of preventive health care through the delivery of personalized hormone therapy, has closed an underwritten public offering of 5,793,500 shares of its Class A common stock by one of its stockholders. According to the update, the shares were sold at a public offering price of $5.35 per share. Biote will not receive any of the proceeds from the sale of the shares offered by the selling stockholder. ROTH MKM acted as sole manager for the offering.
To view the full press release, visit https://ibn.fm/hOYie
About Biote Corp.
Biote is transforming healthy aging through innovative, personalized hormone optimization therapies delivered by Biote-certified medical providers. Biote trains practitioners how to identify and treat early indicators of hormone-related aging conditions, an underserved $7 billion global market, providing affordable symptom relief for patients and driving clinic success for practitioners. For more information, visit the company’s website at www.Biote.com.
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork